Immuneering Corporation (IMRX) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.84
↓-54% vs avg
5yr avg: 1.82
30Y Low1.2·High2.7
ROE
↑
-43.1%
↓+22% vs avg
5yr avg: -55.4%
30Y Low-93%·High-38%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
IMRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Immuneering Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $152M | $290M | $66M | $209M | $128M | $426M | — | — |
| Enterprise Value | $27M | $165M | $34M | $154M | $60M | $356M | — | — |
| P/E Ratio → | -3.30 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | 403.77 | 204.62 | — | — |
| P/B Ratio | 0.84 | 1.33 | 1.59 | 2.31 | 1.17 | 2.73 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
IMRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | 189.87 | 171.19 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
IMRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -43.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 50.1% | 44.6% | 44.6% | 36.3% |
| Operating Margin | — | — | — | — | -16325.8% | -1629.2% | -739.0% | -327.7% |
| Net Profit Margin | — | — | — | — | -15937.3% | -1612.3% | -737.2% | -401.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -43.1% | -43.1% | -92.5% | -53.4% | -38.0% | -50.2% | — | — |
| ROA | -39.4% | -39.4% | -78.6% | -47.5% | -34.9% | -32.7% | -64.9% | -54.7% |
| ROIC | -86.4% | -86.4% | -213.4% | -112.8% | -60.4% | -184.8% | — | — |
| ROCE | -44.5% | -44.5% | -91.6% | -55.9% | -37.6% | -34.4% | -68.7% | -46.3% |
IMRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $129M exceeds total debt of $4M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.10 | 0.05 | 0.04 | 0.03 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.57 | -0.77 | -0.61 | -0.62 | -0.45 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | -20.95 |
Net cash position: cash ($129M) exceeds total debt ($4M)
IMRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Immuneering Corporation's current ratio of 17.50x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 11.35x to 17.50x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.50 | 17.50 | 5.28 | 11.35 | 13.50 | 27.04 | 16.73 | 27.83 |
| Quick Ratio | 17.50 | 17.50 | 5.28 | 11.35 | 13.50 | 27.04 | 16.73 | 27.83 |
| Cash Ratio | 17.16 | 17.16 | 4.82 | 10.92 | 13.10 | 26.48 | 16.44 | 27.28 |
| Asset Turnover | — | — | — | — | 0.00 | 0.01 | 0.06 | 0.14 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | 14.30 | 43.18 | 78.97 | 39.92 |
IMRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Immuneering Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $44M | $30M | $28M | $26M | $26M | $14M | $14M |
Peer Comparison
Compare IMRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 IMRXYou | $152M | -3.3 | — | — | — | — | -43.1% | -86.4% | — |
 ACAD | $4B | 9.2 | 25.1 | 34.3 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.9 | 6.8 | 8.6 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PRTA | $432M | -1.8 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 ARQT | $3B | -187.5 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 EXEL | $13B | 19.1 | 14.6 | 16.0 | 96.4% | 37.6% | 35.5% | 32.1% | 0.2 |
 MGNX | $252M | -3.4 | — | — | 71.1% | -48.7% | -86.9% | -144.1% | — |
 TGTX | $8B | 17.9 | 62.8 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
 RCUS | $2B | -7.2 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 IMVT | $7B | -12.1 | — | — | — | — | -64.8% | — | — |
 NKTR | $1B | -6.1 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
What if you invested $1,000 in IMRX 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in IMRX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs IMRX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationIMRX vs ACAD — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs ACADIA Pharmaceuticals Inc..
Compare NowIMRX — Frequently Asked Questions
Quick answers to the most common questions about buying IMRX stock.
What is Immuneering Corporation's P/E ratio?
Immuneering Corporation's current P/E ratio is -3.3x. This places it at the 50th percentile of its historical range.
What is Immuneering Corporation's ROE?
Immuneering Corporation's return on equity (ROE) is -43.1%. The historical average is -55.4%.
Is IMRX stock overvalued?
Based on historical data, Immuneering Corporation is trading at a P/E of -3.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.